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Summary 
 
Background  
Vaccine eﬀectiveness of pneumococcal conjugate vaccines against culture-conﬁrmed invasive 
pneumococcal disease has been well documented. In the Finnish Invasive Pneumococcal disease (FinIP) 
trial, we reported vaccine eﬀectiveness and absolute rate reduction against laboratory-conﬁrmed 
invasive pneumococcal disease (conﬁrmation by culture or antigen or DNA detection irrespective of 
serotype). Here, we assessed vaccine eﬀectiveness of PHiD-CV10 against clinically suspected invasive 
pneumococcal disease in children by use of diagnoses coded in hospital discharge registers. 
 
Methods  
For this phase 3/4 cluster-randomised, double-blind trial, undertaken between Feb 18, 2009, and Dec 31, 
2011, in municipal health-care centres and the Tampere University Vaccine Research Centre (Finland), 
we randomly assigned (2:2:1:1) 78 clusters into PHiD-CV10 three plus one, PHiD-CV10 two plus one, 
control three plus one, control two plus one groups (26:26:13:13 clusters) to give PHiD-CV10 in either 
three plus one or two plus one schedule (if enrolled before 7 months of age; infant schedules), two plus 
one (if enrolled between 7 and 11 months; catch-up schedules), and two doses at least 6 months apart (if 
enrolled between 12 and 18 months; catch-up schedules). Children were eligible if they had not received 
and were not anticipated to receive any of the study vaccines and had no general contraindications to 
vaccinations. We collected all inpatient and outpatient discharge notiﬁcations from the national hospital 
discharge register with International Classiﬁcation of Diseases (ICD) 10 diagnoses compatible with 
invasive pneumococcal disease or unspeciﬁed sepsis, and veriﬁed data with patient ﬁles. We excluded 
invasive pneumococcal disease cases conﬁrmed by positive culture or DNA/RNA detection from 
normally sterile body ﬂuid. The primary objective was to estimate vaccine eﬀectiveness against all 
register-based non-laboratory-conﬁrmed invasive pneumococcal disease or unspeciﬁed sepsis and 
patient-ﬁle veriﬁed non-laboratory-conﬁrmed invasive pneumococcal disease in infants younger than 7 
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months at enrolment. Masked follow-up lasted from the date of the ﬁrst vaccination to Dec 31, 2011. 
Vaccine eﬀectiveness was calculated against all episodes. This trial is registered with ClinicalTrials.gov, 
numbers NCT00861380 and NCT00839254. 
 
Findings  
We enrolled 47 366 children. On the basis of ICD-10 diagnoses, we recorded 264 episodes of register-
based non-laboratory-conﬁrmed invasive pneumococcal disease or unspeciﬁed sepsis, of which 102 
were patient-ﬁle veriﬁed non-laboratory-conﬁrmed invasive pneumococcal disease. The vaccine 
eﬀectiveness was 50% (95% CI 32–63) in the 30 527 infants with three plus one and two plus one 
schedules combined and the absolute incidence rate reduction was 207 episodes per 100 000 person-
years (95% CI 127–286). The vaccine eﬀectiveness against the patient-ﬁle veriﬁed non-laboratory-
conﬁrmed invasive pneumococcal disease was 71% (95% CI 52–83) in infant three plus one and two 
plus one schedules combined. The absolute rate reduction was 142 episodes per 100 000 person-years 
(95% CI 91–191) in infant cohorts. 
 
Interpretation  
This vaccine-probe analysis is the ﬁrst report showing the eﬀect of pneumococcal conjugate vaccines on 
clinically suspected invasive pneumococcal disease. The absolute rate reduction was markedly higher 
compared with laboratory-conﬁrmed invasive pneumococcal disease, which implies low sensitivity of 
the laboratory-based case deﬁnitions and subsequently higher public health eﬀect of pneumococcal 
conjugate vaccines against invasive pneumococcal disease than previously estimated. 
 
Funding GlaxoSmithKline Biologicals SA and National Institute for Health and Welfare (THL), Finland
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Introduction 
 
High vaccine eﬀectiveness of pneumococcal conjugate vaccines against culture-conﬁrmed invasive 
pneumococcal disease has been well documented both in clinical trials
1
 and observational studies.
2,3
 
However, culture-conﬁrmed invasive pneumococcal disease is a highly speciﬁc endpoint and to what 
extent all true invasive pneumococcal disease cases are detected is unknown. 
The sensitivity of case detection of culture-conﬁrmed invasive pneumococcal disease might be poor 
because patient care seeking might be very early during the disease process or delayed with 
spontaneous recovery; primary care referral to proper diagnosis can be missed and antimicrobial 
treatment started without study of causes; and hospital blood culture practices might be suboptimum. 
Furthermore, the sensitivity of the laboratory detection by culture is not perfect and might be further 
reduced by antimicrobial treatment or inappropriate processing. Lastly, reporting of cases to registers 
can be missed if high-quality procedures are not established. Consequently, assessments of the vaccine 
eﬀect on the basis of culture-conﬁrmed invasive pneumococcal disease most probably underestimate 
the public health burden averted by vaccination programmes.  
We have previously reported that the PHiD-CV10 vaccine eﬀectiveness against laboratory-
conﬁrmed invasive pneumococcal disease (collected through the National Infectious Diseases Register 
[NIDR] in the Finnish Invasive Pneumococcal disease [FinIP] trial) was 94% (95% CI 77–99) and the 
absolute rate reduction (ie, vaccine-preventable incidence) was 75 per 100 000 person-years.
4
  
To estimate the eﬀect of pneumococcal conjugate vaccines on invasive pneumococcal disease more 
comprehensively taking into account the potential suboptimum sensitivity of laboratory-based 
detection, we set to assess vaccine eﬀectiveness of the pneumococcal Haemophilus inﬂuenzae protein 
D conjugate vaccine (PHiD-CV10, Synﬂorix, GlaxoSmithKline, Belgium) against clinically suspected 
invasive pneumococcal disease with hospital discharge register data. 
 
Methods 
 
Trial design and participants 
The FinIP trial was a nationwide phase 3/4 cluster- randomised, double-blind ﬁeld trial done by the 
National Institute for Health and Welfare (THL, Finland). The trial was done in municipal health-care 
centres and their local well-baby clinics (N=651). The Tampere University Vaccine Research Centre 
(TAUVRC) undertook a parallel trial with the same design for acute otitis media, and its participants 
were also followed up for the outcomes of this study.
5
 
The trial design has been previously described.
4 Brieﬂy, children younger than 19 months could be 
enrolled if they had not received and were not anticipated to receive any of the study vaccines and had 
no general contraindications to vaccinations. 
The study protocols were approved by the relevant ethics review boards and competent authorities 
before trial start. Written consent was obtained from a parent or guardian of all participants. The full 
protocol is available online (www.ﬁnip.ﬁ). 
 
Randomisation and masking 
The areas of the health-care centres participating in the trial were divided geographically into 72 
study clusters. TAUVRC contributed to the study in 44 of these clusters and enrolled participants in 
six additional clusters. The treatment was allocated into the 78 clusters (2:2:1:1) into PHiD-CV10 
three plus one, PHiD-CV10 two plus one, control three plus one, and control two plus one groups 
(26:26:13:13 clusters) and stratiﬁed according to the birth cohort size (lower or higher than average), 
TAUVRC trial enrolment (50 of 78 clusters), and urbanity (24 urban and 54 rural clusters).
4
 Details of 
the masking have been presented previously.
4
 
 
Procedures 
The PHiD-CV10 vaccine contains ten pneumococcal serotype polysaccharides (1, 4, 5, 6B, 7F, 9V, 
14, 18C, 19F, and 23F) individually conjugated to carrier proteins: protein D of non-typeable H 
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inﬂuenzae, tetanus, or diphtheria toxoids. We used hepatitis B virus vaccine (10 μg/0•5 mL 
ENGERIX-B, GlaxoSmithKline, Belgium) as a control vaccine for children enrolled younger than 12 
months and hepatitis A virus vaccine (Havrix 720 Junior, 0•5 ml GlaxoSmithKline, Belgium) for 
children enrolled at the age of 12 months or older. 
Enrolled children were vaccinated according to either three plus one or two plus one schedule if 
enrolled before 7 months of age (infant schedules), two plus one if enrolled between 7 and 11 months, 
and two doses at least 6 months apart if enrolled between 12 and 18 months of age (catch-up 
schedules) as described in detail previously.
4
  
The outcome data were collected from the nationwide administrative Care Register for Health Care 
maintained at THL (see http://www.thl.ﬁ/en_US/web/en/ statistics/information/register_ 
descriptions/careregister_healthcare). The Care Register included all notiﬁcations of inpatient and 
outpatient care provided in all public and private hospitals in Finland. The register data included 
hospital and patient identiﬁcation (by unique and permanent personal identity codes assigned to all 
long-term residents in Finland), the initial and ﬁnal ICD-10 diagnoses, admission, and discharge dates, 
the place admitted from and discharged to, and also whether the patient survived or not. The hospitals, 
obliged by law, submit these data to THL in yearly batches. The completeness of the register in 
covering all inpatient and outpatient diagnoses in Finnish hospitals is very good although no validation 
studies of paediatric infectious diseases are available.
6
 
We collected all discharge notiﬁcations of inpatient or outpatient care with available primary or 
either of the ﬁrst two secondary diagnoses of ICD-10 codes compatible with clinical syndromes of 
invasive pneumococcal disease (ICD-10 codes A40.3, B95.3, G00.1, or M00.1) or unspeciﬁed sepsis 
(ICD-10 codes A40.9, A41.9, A49.9, G00, G00.9, I30.1, M00, M00.9, or B95.5) from the Care 
Register (panel 1 and table 1). To ensure that repeated hospital visits and admissions due to the same 
illness were not counted more than once in the analyses, we applied a 90-day episode rule; a new 
episode was judged to start on the day that the patient visited the hospital provided that at least 90 days 
had elapsed from the beginning of the previous episode fulﬁlling the criteria for the case deﬁnition. 
We used the NIDR to identify laboratory-conﬁrmed cases of invasive pneumococcal disease 
(culture-conﬁrmed [ie, positive for Streptococcus pneumoniae in culture in any normally sterile body 
ﬂuid] and probable [ie, positive for S pneumoniae in demonstration of nucleic acid or antigen detection 
tests but negative for S pneumoniae in culture]). We matched these laboratory-conﬁrmed cases of 
invasive pneumococcal disease found in NIDR with cases detected in the Care Register with personal 
identity codes and the date of diagnosis and sampling. We excluded all laboratory- conﬁrmed episodes 
of invasive pneumococcal disease, but not invasive diseases due to other bacteria, from the analyses. 
The results of laboratory-conﬁrmed invasive pneumococcal disease according to NIDR have been 
published previously.
4
 
Patient ﬁles of all identiﬁed episodes of non-laboratory- conﬁrmed invasive pneumococcal disease 
or unspeciﬁed sepsis were collected from the hospitals and the data for the following variables were 
extracted: the ﬁnal diagnoses set by the treating physician (ICD-10 code); blood culture sample 
available (yes or no); result of blood culture test; any other aetiological tests including both bacterial 
and viral assays; ﬁrst and highest C-reactive protein; and ﬁrst and highest blood leucocyte counts. To 
increase the speciﬁcity of the outcome and to validate the register-based diagnoses, we scrutinised all 
the clinical and aetiological patient data to classify the cases in diﬀerent clinical categories (panel 1 
and table 2) by two physician researchers independently of each other (AAP and HN). For the purpose 
of the classiﬁcation, invasive pneumococcal disease was deﬁned as any acute disease resulting in any 
ICD-10 diagnosis listed in table 1 during the hospital period and the patient ﬁle details (especially the 
ﬁnal discharge diagnosis, relevant studies of causes, and the comments by the treating paediatrician) 
suggested pneumococcus as the most probable causative agent for the disease. When the two reviewers 
established discordant categories, the case was classiﬁed independently by a third physician (RS) 
whose verdict established the ﬁnal category if it coincided with the classiﬁcation of either of the two 
primary reviewers. In case all three reviews produced diﬀerent conclusions, the consensus was 
established by a panel including all three. This review was done after the trial was unmasked, but the 
vaccination details could not have been described in the patient ﬁles during the masked study period 
11 
 
 
and the vaccination data were not included in the datasets extracted for review. 
 
Outcomes 
The primary objectives of this study were to estimate both incidence rate ratio (vaccine 
eﬀectiveness) and incidence rate diﬀerence (vaccine preventable incidence) between treatment and 
control groups for register-based non-laboratory-conﬁrmed invasive pneumococcal disease or 
unspeciﬁed sepsis and patient-ﬁle veriﬁed non-laboratory-conﬁrmed invasive pneumococcal disease in 
infants who received at least one dose of either three plus one or two plus one schedule before age 7 
months. The sample size estimation for the FinIP trial was based on the primary objective of the trial—
ie, to show eﬀectiveness against laboratory-conﬁrmed invasive pneumococcal disease.4 
 
Statistical analysis 
Intention-to-treat follow-up for each participant started at the date of the ﬁrst vaccination (trial 
enrolment from Feb 18, 2009, to Oct 5, 2010) and ended on Dec 31, 2011. The trial randomisation 
code was opened in April, 2012. We estimated vaccine eﬀectiveness against all episodes. We 
calculated incidences as arithmetic mean of cluster-speciﬁc incidences in PHiD-CV10 and control 
groups.  
To account for between-cluster variability in the incidence, we used a negative binomial model for 
the analysis of the vaccine eﬀectiveness.7 We grouped frequencies of episodes by cluster and used the 
cluster-speciﬁc person-years as weights in the analysis. When estimating the eﬀectiveness by infant 
schedule, we used a treatment variable in the model as three-level factor (PHiD-CV10 three plus one, 
PHiD-CV10 two plus one, and control). We included factors used for stratiﬁed randomisation in the 
model as explanatory variables. We used the proﬁle likelihood method to estimate the 95% CIs for the 
treatment parameter. We calculated vaccine eﬀectiveness as 1 minus the incidence rate ratio. 
Incidence rate diﬀerence (ie, vaccine-preventable incidence), was calculated as the diﬀerence of 
incidence rate estimates in the PHiD-CV10 and control groups. We used a non-parametric bootstrap 
method to calculate the conﬁdence intervals.8 We used stratiﬁed bootstrap sampling based on levels of 
the stratiﬁcation factors used for randomisation. 
This trial and the nested acute otitis media trial are registered at ClinicalTrials.gov, NCT00861380 
and NCT00839254. 
 
Role of the funding source 
This collaborative study was mainly funded by GlaxoSmithKline Biologicals SA and co-funded by 
the National Institute for Health and Welfare (THL). Both parties were involved in all stages of the 
study planning, conduct, data collection, analyses, and manuscript development. All authors had 
access to all the data and accept responsibility for its validity. All authors agreed on the ﬁnal decision 
to submit for publication. 
 
Results 
47 366 children were enrolled from Feb 18, 2009, to Oct 5, 2010. 45 974 participants received at 
least one dose of correctly assigned vaccine and were included in the intention-to-treat analyses (ﬁgure 
1). The baseline and vaccination data have been published previously.
4
 
We identiﬁed 264 episodes of register-based non-laboratory-conﬁrmed invasive pneumococcal 
disease or unspeciﬁed sepsis. Table 1 shows the diagnosis codes. Five children had two episodes and 
one child had three episodes. 
Table 2 shows the ﬁnal diagnoses of all episodes on the basis of patient-ﬁle review. We noted 102 
episodes (including one child with three episodes) of patient-ﬁle veriﬁed non-laboratory-conﬁrmed 
invasive pneumococcal disease. 
Table 3 shows the baseline characteristics and clinical features of patients with register-based or 
patient-ﬁle veriﬁed non-laboratory-conﬁrmed invasive pneumococcal disease or unspeciﬁed sepsis in 
comparison with patients with laboratory-conﬁrmed invasive pneumococcal disease.4 We recorded no 
fatal cases in any of the patient groups. The clinical courses of all non-laboratory-conﬁrmed case 
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deﬁnition groups were very similar to laboratory-conﬁrmed invasive pneumococcal disease with 
respect to the duration of treatment in hospital and C-reactive protein and leucocyte count values 
during hospital stay. Only the highest leucocyte levels were higher and C-reactive protein values at 
admission tended to be lower in laboratory-conﬁrmed episodes than in the non-laboratory-conﬁrmed 
invasive pneumococcal disease episodes (table 3). 21 of 264 (8%) episodes of register-based non-
laboratory-conﬁrmed invasive pneumococcal disease or unspeciﬁed sepsis had a ﬁnal ICD-10 
diagnosis of pneumonia, which was much lower than laboratory-conﬁrmed invasive pneumococcal 
disease, in which the clinical syndrome was pneumonia in 28% (eight of 29) of the episodes. Acute 
otitis media was listed as a ﬁnal diagnosis at discharge from the hospital in 39 of 264 (15%) episodes 
of register-based non-laboratory- conﬁrmed invasive pneumococcal disease or unspeciﬁed sepsis. This 
ﬁnding was similar in the laboratory- conﬁrmed episodes (ﬁve of 29 [17%]). 
The vaccine eﬀectiveness for the register-based non-laboratory-conﬁrmed invasive pneumococcal 
disease or unspeciﬁed sepsis was 50% for both infant three plus one and two plus one schedules 
combined (95% CI 32–63) and combined catch-up groups (95% CI 14–71; table 4). The absolute rate 
reduction was similar in infant groups (207 episodes per 100 000 person-years) and in combined catch-
up groups (203 episodes). 
The more speciﬁc case deﬁnition of register-based non-laboratory-conﬁrmed invasive 
pneumococcal disease gave higher vaccine eﬀectiveness estimates but the incidence rate reductions 
were lower than for the register- based non-laboratory-conﬁrmed invasive pneumococcal disease or 
unspeciﬁed sepsis (table 5). The vaccine eﬀectiveness was similar for the patient-ﬁle veriﬁed non- 
laboratory-conﬁrmed invasive pneumococcal disease (71% [95% CI 52–83] in infant three plus one 
and two plus one schedules combined and in combined catch-up groups (69%, 95% CI 32–86; table 6). 
The absolute rate reduction was 142 episodes per 100 000 person-years in infant groups and 111 
episodes in catch-up groups.  
The vaccine eﬀect was already seen at 6–11 months of age and persisted at least up to 29 months of 
age (ﬁgure 2). We further explored the relative and absolute eﬀect of PHiD-CV10 with various C-
reactive protein and blood leucocyte cutoﬀ amounts (ﬁrst and highest during admittance to hospital) in 
the case deﬁnitions for the infant cohort. High C-reactive protein value cutoﬀs gave successively 
increased vaccine eﬀectiveness estimates, nearly reaching those shown for laboratory-conﬁrmed 
invasive pneumococcal disease. However, as expected, the absolute reduction decreased with the less 
sensitive endpoint deﬁnitions (appendix). The blood leucocyte concentration cutoﬀs did not have a 
consistent eﬀect on vaccine eﬀectiveness estimates (data not shown). 
The addition of the vaccine-preventable incidence of culture-conﬁrmed and probable invasive 
pneumococcal disease (75 episodes per 100 000 person-years) reported earlier from the same trial
4
 to 
that of the register-based non-laboratory-conﬁrmed invasive pneumococcal disease or unspeciﬁed 
sepsis of our analysis (table 4) resulted in vaccine-preventable incidence of 282 episodes per 100 000 
person-years. This ﬁnding would translate into a number needed to vaccinate of 178 for the infant 
cohorts per 2-year follow-up to prevent one case of laboratory-conﬁrmed or non-laboratory- conﬁrmed 
invasive pneumococcal disease. 
If we assumed the same vaccine eﬀectiveness for the undetected invasive pneumococcal disease as 
reported for culture-conﬁrmed or probable invasive pneumococcal disease, irrespective of serotype 
(vaccine eﬀectiveness point estimate 94%),4 the incidence of the register-based non-laboratory-
conﬁrmed invasive pneumococcal disease or unspeciﬁed sepsis attributable to pneumococcus would be 
estimated at 220 episodes per 100 000 person-years (207/0•94) in the infant control group. Thus, the 
total incidence of clinical invasive pneumococcal disease including both laboratory-conﬁrmed and 
non-conﬁrmed invasive pneumococcal disease episodes would be 300 per 100 000 person-years. 
Therefore, this vaccine-probe design suggests that the sensitivity of the laboratory-based detection of 
invasive pneumococcal disease in the present routine hospital care setting was 27% (80 / [80 + 220]). 
This low sensitivity can partly be explained by failure to obtain blood-culture test (15% of the 
episodes) and the antimicrobial exposure at admission (12% in the non- laboratory-conﬁrmed episodes 
and 0% in laboratory- conﬁrmed). If only episodes with blood culture obtained and no exposure to 
antimicrobials are included (69 of 87 episodes in the infant control cohorts), we estimate the sensitivity 
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of the laboratory-based detection of invasive pneumococcal disease as 31% (80 / [80 + 174]). 
Table 2 shows the ﬁnal categories of acute infections resulting in ICD-10 coding compatible with 
invasive pneumococcal disease or unspeciﬁed sepsis during hospital visit or admittance to hospital. We 
recorded seven episodes for which the patient-ﬁle review resulted in classiﬁcation of no acute infection 
(table 2). In two of these episodes, sepsis was suspected during admittance to hospital, but another 
non-infectious disease was ultimately diagnosed. In two episodes, there was a previous admittance to 
hospital with a sepsis diagnosis and a follow-up visit later than 90 days after the admittance; with our 
deﬁnition, we calculated these as two episodes. Finally, we noted three episodes in which no obvious 
disease compatible with invasive pneumococcal disease or non-speciﬁed sepsis were mentioned in the 
source data available. Thus, the misclassiﬁcation proportion based on erroneous register data entry 
would be estimated at maximum 1% (three of 264). 
The study design also allowed the estimation of the completeness of the National Infectious 
Diseases Register (NIDR), which collects data for culture- conﬁrmed invasive pneumococcal disease 
and probable invasive pneumococcal disease detected by DNA or RNA detection (29 cases).
4
 Blood 
culture had been taken in 225 of 264 (85%) episodes of register-based non- laboratory-conﬁrmed 
invasive pneumococcal disease or unspeciﬁed sepsis, all negative for Streptococcus pneumoniae in 
patient-ﬁle review. Thus, in this dataset with ICD-10 diagnoses compatible with invasive 
pneumococcal disease and unspeciﬁed sepsis, the completeness of the reporting of positive cases to 
NIDR was 100% (29 / [29 + 0]). 
 
Discussion 
Our report is the ﬁrst to show the eﬀect of a pneumococcal conjugate vaccine on a clinical 
syndrome compatible with invasive pneumococcal disease that remains non-conﬁrmed by laboratory 
assays, and implies much higher public health value of pneumococcal conjugate vaccines than 
previously reported. All previous clinical trials have relied on laboratory-based microbiological case 
deﬁnitions. All infant and catch-up vaccination schedules showed high eﬀectiveness, although the 
results for catch-up schedule with enrolment at 7–11 months’ age were not statistically signiﬁcant. The 
vaccine eﬀectiveness point estimates were actually higher for the infant two plus one schedule than for 
the three plus one schedule, but the conﬁdence intervals were overlapping. Furthermore, we have 
reported comparable vaccine eﬀectiveness estimates for the infant three plus one and two plus one 
schedules for all other study outcomes of culture-conﬁrmed invasive pneumococcal disease,4 
pneumonia,
9
 and antimicrobial purchases.
10
 
We are aware of only two published studies
11,12 
by Simonsen and colleagues in which the same kind 
of discharge register-based endpoint was used (panel 2). In these observational studies, the 
investigators used register-based invasive pneumococcal disease treatment in hospital from a hospital 
discharge register as the endpoint, but they did not have data for whether these cases were culture-
conﬁrmed. However, incidences of the register-based invasive pneumococcal disease endpoint were 
only about half of those reported for culture- conﬁrmed disease with treatment in hospital.2,13 These 
data suggested that most of the cases were actually blood-culture positive. Nevertheless, researchers 
noted a large relative reduction during the 7-valent pneumococcal conjugate vaccine vaccination era 
compared with the baseline before the vaccinations and further reduction after the introduction of the 
13-valent pneumococcal conjugate vaccine.
11,12
 
Additionally, pneumococcal conjugate vaccines have reduced other pneumococcus-related clinical 
endpoints such as pneumonia and acute otitis media both in clinical trials and in observational 
studies.
1,14,15
 The vaccine probe design
16
 used in this report has also been exploited in circumstances in 
which information about disease cause was diﬃcult to obtain or was deemed to have low sensitivity. 
Examples include estimation of vaccine- preventable invasive disease and pneumonia caused by H 
inﬂuenzae17 and the exploration of pneumococcal vaccine-preventable pneumonia burden by use of 
various diﬀerent case deﬁnitions.18 
Our estimates of vaccine eﬀectiveness fall between those for culture-conﬁrmed invasive 
pneumococcal disease
1,4 and radiologically conﬁrmed pneumonia.19 Similar to pneumonia, the vaccine 
eﬀect was the net reduction in disease due to the ten vaccine serotypes combined, and potentially also 
10 
 
 
due to cross-reactive vaccine-related serotypes, plus the net increase because of replacement by non-
vaccine serotypes. Non-typeable H inﬂuenzae is a rare cause of invasive-like disease, and despite 
protein D carrier in the vaccine, is unlikely to contribute to our ﬁndings. The high vaccine 
eﬀectiveness we recorded (especially for the patient-ﬁle veriﬁed non- conﬁrmed invasive 
pneumococcal disease), further augmented with various C-reactive protein cutoﬀ concentrations, 
clinical features, and health-care utilisation indistinguishable from culture-conﬁrmed invasive 
pneumococcal disease, suggested that we had discovered true cases of invasive pneumococcal disease 
that had gone undetected despite collection of blood for appropriate culture. In this vaccine-probe 
analysis, we also noted that the paediatricians in Finnish hospitals could accurately recognise the 
vaccine-preventable clinical syndrome of pneumococcal bacteraemia. It could be argued that because 
of the non-speciﬁcity of the endpoints, the case deﬁnitions included other pneumococcal disease 
syndromes, such as lower and upper respiratory infections. However, only a small proportion of non- 
laboratory-conﬁrmed invasive pneumococcal disease episodes also had the primary discharge 
diagnosis of pneumonia or acute otitis media. Thus, the eﬀect on the endpoints cannot be solely 
explained by vaccine eﬀect on clinical pneumonia and upper respiratory infections, especially because 
the reported vaccine eﬀectiveness estimates against clinical pneumonia9 and respiratory tract 
infections
10
 were far below those for non-conﬁrmed invasive pneumococcal disease in our study. 
For the most sensitive endpoint of register-based non- conﬁrmed invasive pneumococcal disease or 
unspeciﬁed sepsis, the vaccine eﬀectiveness estimates were lower than for other endpoints because of 
the lower speciﬁcity of this endpoint (table 2). However, the rationale of this deﬁnition was to be 
highly sensitive to capture the vaccine-preventable disease incidence as completely as possible. 
Indeed, the absolute reduction for this outcome was higher than for other endpoints, which suggests 
that more episodes of true vaccine-preventable cases were captured with this endpoint than with the 
more stringent endpoints. 
The vaccine-preventable incidence can be seen as the most pertinent estimate in the assessment of 
the public health eﬀect of the vaccine. The vaccine-preventable incidence of non-laboratory-conﬁrmed 
invasive pneumococcal disease in this study was 1•1–2•8 times higher than that of culture-conﬁrmed 
or probable invasive pneumococcal disease reported earlier from the same trial setting.
4 
The main 
reason for this additional disease burden seems to be the low sensitivity of the blood culture. Even if a 
blood culture was taken in most of the episodes, the samples remained culture-negative. In a study of 
adults with presentation of severe sepsis, the blood culture was positive in 45% of cases.
20
 In more 
than half of the culture-negative cases an infectious cause was suspected, although not conﬁrmed. In a 
paediatric study of clinical syndromes compatible with invasive pneumococcal disease (mainly 
pneumonia), the blood culture was positive for pneumococcus in 4% of cases, but real-time PCR on 
whole blood sample was positive in up to 24% (ie, 5•5 times higher).21 
This was a nationwide, double-blind randomised trial with a large enrolment proportion (38% of 
age-eligible birth cohorts). We collected outcome data from a nationwide established register. The 
Care Register collects discharge notiﬁcations of routine care for all hospital individual outpatient visits 
and inpatient ward admissions. We collected data for all discharge notiﬁcations including emergency 
room discharge notiﬁcations. Therefore, our dataset included the ﬁrst working diagnoses at emergency 
rooms with the ﬁrst suspicion of diagnoses at admission, not only the ﬁnal diagnoses assigned after 
further clinical assessment and follow-up at discharge from the hospital, which further increased the 
sensitivity of the case detection. 
To address the potential non-speciﬁcity of the clinical diagnoses assigned, we veriﬁed all clinical 
patient-ﬁle data to establish classiﬁcation considering all clinical data for the whole period of treatment 
in hospital and to identify the most probable cases of non-laboratory- conﬁrmed invasive 
pneumococcal disease (table 2). As expected, the vaccine eﬀectiveness estimates were higher for the 
patient-ﬁle veriﬁed endpoint than for other endpoints suggesting higher speciﬁcity. However, the eﬀect 
of the patient-ﬁle veriﬁcation was not crucial because the register-based endpoints also gave high 
vaccine eﬀectiveness estimates and we recorded the highest vaccine-preventable incidence for the 
most sensitive register-based outcome. 
The data linkage for enrolled participants and their register notiﬁcations was done with the Personal 
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Identity Code, which is unique and permanent for all Finnish citizens and long-term residents. 
Therefore, all nationwide notiﬁcations can be linked to a participant with this code. The Personal 
Identity Code includes a check digit (see http://www.vrk.ﬁ/default. aspx?id=45) preventing false 
entries and is correct in 99•5% of all discharge notiﬁcations.6 Therefore, we might have missed only a 
few episodes diagnosed and treated abroad outside of the Finnish hospitals. However, we might have 
missed cases if the appropriate ICD-10 code was not entered in the discharge notiﬁcation. In this case 
of suboptimum sensitivity of case detection, the estimates of vaccine eﬀectiveness would probably not 
be aﬀected in the randomised design, but the incidence of non-conﬁrmed invasive pneumococcal 
disease, and also vaccine preventable disease incidence, would be even higher than we recorded. 
Diagnostic practices might vary between hospitals, and the eﬀect of this bias might be a concern in 
cluster- randomised trials. Finland has 20 public hospitals, which cover the whole country. 16 hospitals 
served both PHiD-CV10 and control clusters in our study. The remaining four hospitals, which 
covered roughly 10% of the study population, served PHiD-CV10 clusters only. Exclusion of these 
clusters from the analyses had no eﬀect on the results (data not shown). 
Our ﬁnding of additional disease burden was detected in addition to the laboratory-conﬁrmed 
invasive pneumococcal disease (incidence 80 per 100 000 person- years in the infant cohort in the 
control clusters).
4 This ﬁnding is concordant with the national long-term average for culture-conﬁrmed 
invasive pneumococcal disease before pneumococcal conjugate vaccines vaccination era of roughly 60 
per 100 000 person-years in children younger than 2 years. The Finnish incidences of invasive 
pneumococcal disease are far higher than reported for most countries in Europe.
22 
Thus, the high 
additional pneumococcal disease burden presented in this report is not due to poor detection of the 
culture-conﬁrmed disease. In the pre-pneumococcal conjugate vaccines era invasive pneumococcal 
disease incidence was much higher in the USA,
2
 partly because of more sensitive blood culture 
detection including sampling from well- appearing febrile children, so-called occult pneumococcal 
bacteraemia,
23
 diagnosed and treated in outpatient settings. Actually, the rates of admittance to hospital 
with invasive pneumococcal disease in the USA
2
 are concordant with the Finnish rates. Our cases 
might have been bacteraemic at some point during the course of illness but at the time of blood 
sampling, they were, by deﬁnition, negative in blood culture and almost invariably treated in the 
hospital. 
The diagnostic, treatment, and coding practices vary substantially by country, area, and by time. 
However, pneumococcal disease is present everywhere. We believe that our results are generalisable 
and valid also for other high-income countries. Although true diﬀerences exist in the incidence of 
invasive pneumococcal disease, the low incidences of culture- conﬁrmed invasive pneumococcal 
disease are most probably associated with low sensitivity of the case detection. Thus, on the basis of 
our ﬁndings, especially in countries with low incidence of culture-conﬁrmed invasive pneumococcal 
disease, the eﬀect of pneumococcal conjugate vaccines is probably much higher than would be 
expected on the basis of laboratory-conﬁrmed disease. 
This is the ﬁrst clinical trial report showing the eﬀect of pneumococcal conjugate vaccines on 
clinically suspected non-laboratory-conﬁrmed invasive pneumococcal disease, and our data suggest a 
higher public health value of pneumococcal conjugate vaccines than previously estimated. Although 
this study might still miss a large disease burden that remains undetected because of many factors 
aﬀecting care seeking and diagnostics at the primary care level, the vaccine probe design16 enables 
deeper understanding of the public health value of the pneumococcal conjugate vaccines. This point 
should also be taken into account in the future health economic analyses of pneumococcal conjugate 
vaccines. 
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Panel 1: Deﬁnitions of outcomes 
Register-based non-laboratory-conﬁrmed invasive pneumococcal disease or unspeciﬁed sepsis 
• Deﬁned as an episode to which any ICD-10 code compatible with invasive pneumococcal disease or 
unspeciﬁed sepsis had been assigned in the Care Register without conﬁrmation as invasive pneumococcal 
disease by laboratory assays (culture or DNA/RNA detection from a normally sterile site of the body). This is 
the most sensitive outcome, out of which the following two more speciﬁc subgroup deﬁnitions were formed. 
 
Register-based non-laboratory-conﬁrmed invasive pneumococcal disease 
• Deﬁned as an episode to which ICD-10 code compatible with invasive pneumococcal disease had been 
assigned in the Care Register as ﬁnal discharge diagnosis without conﬁrmation as invasive pneumococcal 
disease by laboratory assays. 
 
Patient-ﬁle veriﬁed non-laboratory-conﬁrmed invasive pneumococcal disease 
• The ﬁrst outcome also had to be classiﬁed as suspected invasive pneumococcal disease in the 
investigators’ patient-ﬁle review. 
 
ICD=International Classiﬁcation of Diseases. 
 
 
 
 
 
 
 
Panel 2: Research in context 
 
Systematic review 
We searched PubMed and Cochrane Library for reports published in English between 
Jan 1, 2000, and May 27, 2014, with the following search terms in any ﬁelds: “eﬃcacy” or “eﬀectiveness” and 
“clinical trial” or “controlled” and “conjugate vaccine” and “invasive pneumococcal disease* OR invasive 
pneumococcal*”. We found no publications of clinical trials with a similar outcome of clinically suspected non-
laboratory-conﬁrmed invasive pneumococcal disease. Two observational studies11,12 with a register-based 
outcome of patients with a diagnosis of invasive pneumococcal disease admitted to hospital were found with 
documentation of both direct and indirect vaccine eﬀect when comparing post-PCV era with the pre-
introduction era. In these studies, the culture-conﬁrmed cases were not excluded because no data for these were 
available. However, several clinical trials and observational studies have documented the substantial eﬀect of 
the pneumococcal conjugate vaccines on laboratory-conﬁrmed invasive pneumococcal disease and on clinical 
endpoints of pneumonia and acute otitis media. 
 
Interpretation 
Our study is the ﬁrst to show the eﬀect of a pneumococcal conjugate vaccine on clinically deﬁned suspected 
non-laboratory-conﬁrmed invasive pneumococcal disease. In the same study,4 the incidence of laboratory-
conﬁrmed invasive pneumococcal disease (80 per 
100 000 person-years) was among the highest reported in Europe for infants. On top of this, the present vaccine-
probe design in the randomised clinical trial setting detected nearly three times as high additional disease burden 
than that detected with laboratory- based outcomes. The result is that the invasive pneumococcal disease burden 
is grossly underestimated by the low sensitivity of the blood culture, probably to an even higher degree in 
countries with low reported incidences of laboratory-conﬁrmed invasive pneumococcal disease.  
  
Table 1. ICD-10 codes compatible with IPD or unspecified sepsis  
ICD-10 code Diagnosis in text Distribution of episodes, 
N total 264* 
A40.3† Sepsis due to Streptococcus pneumoniae 86 
A40.9 Streptococcal sepsis, unspecified 13 
A41.9 Sepsis, unspecified organism 92 
A49.9 Bacterial infection, unspecified 68 
G00 Bacterial meningitis, not elsewhere classified 0 
G00.1† Pneumococcal meningitis 0 
G00.9 Bacterial meningitis, unspecified 1 
I30.1 Infective pericarditis 0 
M00 Pyogenic arthritis 0 
M00.1† Pneumococcal arthritis and polyarthritis 0 
M00.9 Pyogenic arthritis, unspecified 3 
B95.3† Streptococcus pneumoniae as the cause of diseases classified elsewhere 1 
B95.5 Unspecified streptococcus as the cause of diseases classified elsewhere 0 
 * All cases included in the case definition of register-based non-laboratory-confirmed IPD or unspecified sepsis 
† ICD-10 code for diseases caused by Streptococcus pneumoniae, these diagnoses when present as final discharge diagnoses 
included in the case definition of register-based non-laboratory-confirmed IPD  
  
Table 2. Episodes of register-based non-laboratory-confirmed IPD or unspecified sepsis as classified in the patient file review 
 Infants  Catch-up  
 PHID-CV10 
3+1 
PHID-CV10 
2+1 
Control 
3+1/2+1 
 PHID-CV10 
catch-up 
Control 
catch-up 
Total 
Follow-up years 20 630 19 793 20 427  23 476 11 473 95 799 
Category        
Patient-file verified non-laboratory-confirmed IPD        
Suspected IPD, urine antigen positive - - 2  - 1 3 
Suspected IPD, without any laboratory indication of pneumococcal aetiology 16 8 41  13 21 99 
Not verified as non-laboratory-confirmed IPD in patient file review        
Invasive non-pneumococcal disease (ID), culture-confirmed 1* - 1†  1* - 3 
Invasive disease (ID), suspected, not specified 17 7 17  13 9 63 
Urinary tract infection, culture-confirmed 8 3 2  1 3 17 
Urinary tract infection, clinical diagnosis - 1 1  - - 2 
Other bacterial infection, culture-confirmed - - 1  3 1 5 
Other bacterial infection, clinical diagnosis 1 5 6  5 7 24 
Viral infection, etiology demonstrated - 2 -  - - 2 
Viral infection, clinical diagnosis 4 4 10  4 1 23 
Respiratory infection, not specified 6 2 4  3 1 16 
No acute infection  2 - 2  3 - 7 
Total 55 32 87  46 44 264 
*both due to Streptococcus viridans species, the other in an immunocompromised host 
† both Haemophilus influenzae and Moraxella catarrhalis detected in the one blood culture sample 
 
  
Table 3. Baseline characteristics and clinical course of the episodes in all study cohorts  
 Laboratory-
confirmed IPD* 
Register-based  
non-laboratory-
confirmed IPD or 
unspecified sepsis 
Register-based  
non-laboratory-
confirmed IPD† 
Patient-file verified  
non-laboratory-
confirmed IPD† 
Number of episodes 29 264 71 102 
Age in months, mean (IQR)  19 (12-20) 19 (12-25) 20 (13-27) 20 (13-25) 
Male 19 (66%) 148 (56%) 37 (52%) 62 (61%) 
Underlying disease 2 (7%) 27 (10%) 4 (6%) 6 (6%) 
Underlying immunosuppressive disease  0 7 (3%) 0 0 
Antimicrobial exposure at admission 0 32 (12%) 6 (8%) 9 (9%) 
CRP at admission, median (IQR) 50 (35-139) 92 (42-146) 104 (45-146) 103 (45-137) 
CRP, highest during the hospitalization, median (IQR) 108 (57-234) 116 (59-174) 118 (64-181) 118 (54-172) 
Blood leukocyte count at admission, median (IQR) 25.7 (20.3-32.5) 22.0 (15.4-27.2) 25.2 (20.5-29.0) 25.0 (20.5-29.0) 
Blood leukocyte count, highest during the hospitalization, median (IQR) 29.6 (22.3-35.1) 22.3 (16.0-27.3)‡ 25.2 (20.5-29.0)‡ 25.0 (20.5-29.0)‡ 
Hospitalized  29 (100%) 251 (95%) 68 (96%) 101 (99%) 
Duration of hospitalization in days, median (IQR) 2 (1-4) 2 (1-3) 2 (1-2) 2 (1-2) 
* Published earlier4 
† These episodes are a subgroup of the register-based non-laboratory-confirmed IPD or unspecified sepsis  
‡ Statistically significant difference in comparison to laboratory-confirmed IPD (Kolmogorov-Smirnov test) 
 
 
 
  
Table 4. Episodes of register-based non-laboratory-confirmed IPD or unspecified sepsis* and the vaccine effectiveness for the 10-valent PHiD-CV during 
intention-to-treat follow-up  
 Number of episodes Follow-up time, 
person-years 
Episodes per 
100 000 person-
years, cluster-
specific averages  
Vaccine 
effectiveness 
(VE) 
Incidence rate difference, 
cluster-specific averages  
Register-based non-laboratory-confirmed IPD or 
unspecified sepsis*, in the various study cohorts 
PHiD-CV10 
group 
Control 
group 
PHiD-CV10 
group 
Control 
group 
PHiD-CV10 
group 
Control 
group 
VE point 
estimate 
(%) 
95% CI Reduction per 
100 000 
person-years 
95% CI 
3+1 and 2+1 schedule combined from dose 1 87 87 40423 20427 212•9 421•5 50 32-63 207 127-286 
3+1 schedule from dose 1 55 87 20630 20427 274•7 421•5 38 13-56 153 62-245 
2+1 schedule from dose 1 32 87 19793 20427 151•2 421•5 62 43-75 273 200-346 
Catch-up 7-11 months 18 14 8672 4317 211•2 321•7 37 -43-71 112 -83-314 
Catch-up 12-18 months 28 30 14804 7156 159•4 404•7 56 16-78 249 76-419 
*Any of the following ICD-10 codes entered in any discharge notifications: A40.3, A40.9, A41.9, A49.9, G00, G00.1, G00.9, I30.1, M00, M00.1, M00.9, B95.3, or B95.5 
 
  
Table 5. Episodes of register-based non-laboratory-confirmed IPD* and the vaccine effectiveness for the 10-valent PHiD-CV during intention-to-treat follow-up  
 Number of 
episodes 
Follow-up time, 
person-years 
Episodes per 
100 000 person-
years, cluster-
specific averages 
Vaccine 
effectiveness (VE) 
Incidence rate difference, 
cluster-specific averages  
Register-based non-laboratory-confirmed IPD* 
in the various study cohorts 
PHiD-CV10 
group 
Control 
group 
PHiD-CV10 
group 
Control 
group 
PHiD-CV10 
group 
Control 
group 
VE point 
estimate 
(%) 
95% CI Reduction per 
100 000 
person-years 
95% CI 
3+1 and 2+1 schedule combined from dose 1 19 28 40423 20427 46•2 125•9 65 35-81 81 34-126 
register-based, 3+1 schedule from dose 1 14 28 20630 20427 70•9 125•9 50 4-75 58 1-112 
2+1 schedule from dose 1 5 28 19793 20427 21•5 125•9 81 54-94 104 64-143 
Catch-up 7-11 months 4 3 8672 4317 39•1 77•9 44 -227-90 40 -41-120 
Catch-up 12-18 months 7 10 14804 7156 43•6 112•3 68 -2-90 70 -14-165 
*Any of the following ICD-10 codes entered as final discharge diagnoses: A40.3, B95.3, G00.1 or M00.1  
  
Table 6. Episodes of patient-file verified non-laboratory-confirmed IPD* and the vaccine effectiveness for the 10-valent PHiD-CV during intention-to-treat follow-
up  
 Number of  
episodes 
Follow-up time, 
person-years 
Episodes per 
100 000 person-
years, cluster-
specific averages 
Vaccine 
effectiveness (VE) 
Incidence rate difference, 
cluster-specific averages  
patient-file verified non-laboratory-confirmed 
IPD* in the various study cohorts 
PHiD-CV10 
group 
Control 
group 
PHiD-CV10 
group 
Control 
group 
PHiD-CV10 
group 
Control 
group 
VE point 
estimate 
(%) 
95% CI Reduction per 
100 000 
person-years 
95% CI 
3+1 and 2+1 schedule combined from dose 1 24 43 40423 20427 59•3 199•9 71 52-83 142 91-191 
3+1 schedule from dose 1 16 43 20630 20427 82•3 199•9 63 34-80 121 58-182 
2+1 schedule from dose 1 8 43 19793 20427 36•2 199•9 80 60-92 168 122-212 
Catch-up 7-11 months 6 7 8672 4317 58•8 155•0 63 -39-91 98 -24-227 
Catch-up 12-18 months 7 15 14804 7156 43•7 170•9 78 45-92 127 40-220 
*Any of the following ICD-10 codes entered in any discharge notifications: A40.3, A40.9, A41.9, A49.9, G00, G00.1, G00.9, I30.1, M00, M00.1, M00.9, B95.3, or B95.5, 
patient-file verified as non-laboratory-confirmed IPD 
  
  
Figure 1. Trial profile 
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The three plus one and two plus one clusters diﬀered only for the infant schedules. Catch-up schedules were identical for the three plus one and two plus one clusters and were always combined for the 
analyses * 3 subjects not randomised nor vaccinated, ** includes one subject withdrawn from the register follow-up during the blinded follow-up period 
~125 000 Finnish-speaking or Swedish-speaking parents of age-eligible children  
identified in population register contacted by mailed invitation letters 
 ~77000 did not participate  
47 366 children enrolled 
41188 in study 043 (NCT00861380) 
6178 in study 053 (NCT00839254)*  
15878 subjects 
 infants <7 months, N=10275 
 catch-up 7-11 months, N=2169 
 catch-up 12-18 months, N=3434 
 
15368 subjects 
 infants <7 months, N=10426 
 catch-up 7-11 months, N=1761 
 catch-up 12-18 months, N=3181 
 
8442 subjects 
 infants <7 months, N=5550 
 catch-up 7-11 months, N=1161 
 catch-up 12-18 months, N=1731 
 
7675 subjects 
 infants <7 months, N=5259 
 catch-up 7-11 months, N=855 
 catch-up 12-18 months, N=1561 
 
2 excluded 
 infants <7 months,  
o 2 with no vaccinations 
503 excluded 
 infants <7 months,  
o 371 due to randomisation error 
o 1 with no vaccinations 
 catch-up 7-11 months,  
o 50 due to randomisation error 
 catch-up 12-18 months 
o 81 due to randomisation error 
 
883 excluded 
 infants <7 months,  
o 605 due to randomisation error 
o 4 with no vaccinations 
 catch-up 7-11 months 
o 108 due to randomisation error 
 catch-up 12-18 months,  
o 166 due to randomisation error 
 
1 excluded 
 catch-up 7-11 months,  
o 1 with source documents lost 
 
14865 subjects 
o infants <7 months, N=10054** 
o catch-up 7-11 months, N=1711 
o catch-up 12-18 months, N=3100 
 
7559 subjects 
o infants <7 months, N=4941 
o catch-up 7-11 months, N=1053 
o catch-up 12-18 months, N=1565 
 
7674 subjects 
 infants <7 months, N=5259** 
 catch-up 7-11 months, N=854 
 catch-up 12-18 months, N=1561 
 
78 randomised clusters (ratio 2:2:1:1) 
PHiD-CV10 3+1 (26 clusters) PHiD-CV10 2+1 (26 clusters) Control 3+1 (13 clusters) Control 2+1 (13 clusters) 
15876 subjects 
 infants <7 months, N=10273 
 catch-up 7-11 months, N=2169 
 catch-up 12-18 months, N=3434 
 
  
Figure 2. Incidence of patient-file verified non-laboratory-confirmed IPD by treatment and age group in children enrolled before 7 months of age 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Supplement table 1. Episodes of register-based non-laboratory-confirmed IPD or unspecified sepsis with various CRP cut-off levels as additional criteria and 
the vaccine effectiveness for the 10-valent PHiD-CV during intention-to-treat follow-up, 3+1 and 2+1 schedule combined from dose 1 
  Number of  
episodes 
Episodes per  
100 000 person-years,  
cluster-specific averages 
Vaccine 
effectiveness (VE) 
Incidence rate difference, 
cluster-specific averages  
Endpoint definition  PHiD-CV10 
group  
N=20 327 
Control 
group 
N=10 200 
PHiD-CV10 
group 
Control 
group 
VE point 
estimate 
(%) 
95% CI Reduction per 
100 000 
person-years 
95% CI 
Non-laboratory-confirmed IPD or unspecified sepsis* 87 87 212•9 421•5 50 32-63 207 127-286 
Non-laboratory-confirmed IPD or unspecified sepsis, 
CRP>40 mg/l, first 
60 69 148 342 56 38-69 192 131-251 
Non-laboratory-confirmed IPD or unspecified sepsis, 
CRP>40 mg/l, highest during hospitalization  
70 76 171 374 54 36-67 201 126-275 
Non-laboratory-confirmed IPD or unspecified sepsis, 
CRP>80 mg/l, first 
41 51 96 259 59 39-73 162 104-220 
Non-laboratory-confirmed IPD or unspecified sepsis, 
CRP>80 mg/l, highest during hospitalization 
47 58 111 293 59 40-72 181 120-240 
Non-laboratory-confirmed IPD or unspecified sepsis, 
CRP>120 mg/l, first 
22 31 51 158 65 40-80 105 61-151 
Non-laboratory-confirmed IPD or unspecified sepsis, 
CRP>120 mg/l, highest during hospitalization 
28 46 64 238 69 51-81 173 115-233 
*First row as in article table 4 for comparison. 
 
  
Supplement table 2. Episodes of patient-file verified non-laboratory-confirmed IPD with various CRP cut-off levels as additional criteria and the vaccine 
effectiveness for the 10-valent PHiD-CV during intention-to-treat follow-up, 3+1 and 2+1 schedule combined from dose 1 
  Number of episodes Episodes per  
100 000 person-years,  
cluster-specific averages 
Vaccine 
effectiveness (VE) 
Incidence rate difference, 
cluster-specific averages  
Endpoint definition  PHiD-CV10 
group 
N=20 327 
Control 
group 
N=10 200 
PHiD-CV10 
group 
Control 
group 
VE point 
estimate 
(%) 
95% CI Reduction per 
100 000 
person-years 
95% CI 
Non-laboratory-confirmed IPD* 24 43 59•3 199•9 71 52-83 142 91-191 
Non-laboratory-confirmed IPD, CRP>40 mg/l, first  16 38 41 180 79 63-88 139 95-182 
Non-laboratory-confirmed IPD, CRP>40 mg/l, highest during 
hospitalization  
19 41 48 190 77 60-87 143 96-189 
Non-laboratory-confirmed IPD, CRP>80 mg/l, first 11 30 29 142 81 64-91 113 72-154 
Non-laboratory-confirmed IPD, CRP>80 mg/l, highest during 
hospitalization 
11 32 29 150 83 67-92 121 79-161 
Non-laboratory-confirmed IPD, CRP>120 mg/l, first 5 18 13 85 86 65-95 72 44-98 
Non-laboratory-confirmed IPD, CRP>120 mg/l, highest during 
hospitalization 
6 25 15 121 88 72-95 106 69-143 
*First row as in article table 6 for comparison.  
 
  
Supplement figure. Graphic presentation of the relative incidences and vaccine-preventable disease incidences (VPDI) for case definitions of confirmed and 
non-laboratory-confirmed IPD or unspecified sepsis in the FinIP trial infant cohorts 
 
Graph area Definition Incidence per 100 000 person-years
Whole white circle Care notifications with ICD-10 diagnoses listed in Table 1
Whole white circle minus the yellow circle Case definition 1 (excl. laboratory-confirmed IPD) 422
Lower half of the white circle minus the yellow circle Case definition 3 (excl. laboratory-confirmed IPD) 200
Yellow circle Laboratory-confirmed IPD 80
Light blue oval with fill Total VPDI (1+2+3) 282
VPDI 1 Laboratory-confirmed IPD prevented by PHiD-CV10 75
VPDI 2 Case definition 3 disease prevented by PHiD-CV10 142
VPDI 2+VPDI 3 Case definition 1 disease prevented by PCV10 142 + 65 = 207  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Disease preventDisease 
preventable by PCV10 
able by PCV10 
Laboratory-
confirmed IPD 
VPDI 1 
Case definition 3: Patient-file 
verified non-laboratory- 
confirmed IPD 
Yellow circle area outside the white circle: 
Bacteraemic pneumonia, ICD-10 diagnosis 
compatible with CAP 
VPDI 3 
 
VPDI 2 
 
 
PHiD-CV10 VPDI 
 
 
 
 
 
 
 
PHiD-CV10 VPDI 
 
Case definition 1: 
Register-based non-laboratory-
confirmed IPD or unspecified sepsis 
 
